Valuation: Valneva SE

Market Cap 48Cr 54Cr 45Cr 41Cr 77Cr 5.18TCr 77Cr 540.34Cr 210.23Cr 2.64TCr 201.98Cr 197.63Cr 8.5TCr P/E 2026 *
-5.81x
P/E 2027 * 9.16x
Enterprise Value 61Cr 69Cr 57Cr 52Cr 98Cr 6.63TCr 99Cr 690.87Cr 268.79Cr 3.38TCr 258.25Cr 252.68Cr 11TCr EV / Sales 2026 *
4.06x
EV / Sales 2027 * 1.91x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.87%
1 week-7.83%
Current month-5.79%
1 month-11.66%
3 months+10.52%
6 months-0.85%
Current year-31.33%
1 week 2.47
Extreme 2.466
2.81
1 month 2.47
Extreme 2.466
2.98
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-7.83%-47.58%-51.74% 54Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-0.37%-3.81%+19.51%+78.12% 5.74TCr
+1.63%-1.61%+3.16%+36.89% 4.76TCr
+0.50%+3.33%+347.53%+725.26% 4.43TCr
+2.21%-2.79%+28.48%+33.15% 4.25TCr
+0.93%-1.91%+4.48%+110.92% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.56%+4.53%+31.34%+26.92% 2.85TCr
+1.10%-1.33%-7.03%-11.00% 2.43TCr
Average +1.22%-1.01%+43.86%+109.68% 3.91TCr
Weighted average by Cap. +1.46%-0.85%+58.05%+136.59%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.63TCr 24Cr 169.99Cr 66Cr 832.02Cr 64Cr 62Cr 2.67TCr 28Cr 32Cr 26Cr 24Cr 45Cr 3.06TCr 46Cr 318.99Cr 124.11Cr 1.56TCr 119.24Cr 116.67Cr 5.02TCr
Net income -8.11Cr -9.09Cr -7.56Cr -6.88Cr -13Cr -875.68Cr -13Cr -91Cr -36Cr -446.93Cr -34Cr -33Cr -1.44TCr 5.31Cr 5.95Cr 4.94Cr 4.5Cr 8.47Cr 572.94Cr 8.54Cr 60Cr 23Cr 292.42Cr 22Cr 22Cr 939.95Cr
Net Debt 13Cr 15Cr 12Cr 11Cr 21Cr 1.44TCr 22Cr 150.53Cr 59Cr 736.77Cr 56Cr 55Cr 2.37TCr 6.25Cr 7Cr 5.82Cr 5.3Cr 9.98Cr 674.47Cr 10Cr 70Cr 27Cr 344.24Cr 26Cr 26Cr 1.11TCr
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
05/26/05 €2.553 +0.87% 3,85,656
02/26/02 €2.531 -3.06% 6,20,259
01/26/01 €2.611 -3.65% 3,52,536
30/26/30 €2.710 +0.86% 2,21,037
29/26/29 €2.687 -3.00% 2,18,548
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.531EUR
Average target price
6.193EUR
Spread / Average Target
+144.68%

Quarterly revenue - Rate of surprise